论文部分内容阅读
目的探讨不同抗病毒治疗方案对不同时期慢性乙型肝炎的临床效果。方法选取2015年10月—2016年10月周口市中心医院收治的慢性乙型肝炎患者112例,按照不同的治疗方法分为研究组(56例)行替诺福韦治疗,对照组(56例)行拉米夫定耐药后加用阿德福韦酯,对比两组临床效果情况。结果研究组治疗12周和治疗24周后的HBV-DNA不可测率值均显著优于对照组,比较差异具统计学意义(P<0.05),第108周两组患者的HBV-DNA不可测率值差异无统计学意义(P>0.05);研究组HBe Ag消失率和HBe Ag/抗-HBe Ag血清转换率均优于对照组,比较差异具统计学意义(P<0.05);研究组不良发应发生率略低于对照组,但差异无统计学意义(7.14%vs 16.04%,P>0.05)。结论慢性乙型肝炎患者行替诺福韦治疗可有效降低患者耐药性发生率,提高抗病毒效果,值得临床推广。
Objective To investigate the clinical effects of different antiviral treatment regimens on chronic hepatitis B at different stages. Methods One hundred and twelve patients with chronic hepatitis B admitted to Central Hospital of Zhoukou from October 2015 to October 2016 were divided into study group (56 cases) treated with tenofovir and control group (56 cases ) With lamivudine plus adefovir dipivoxil-resistant, compared the clinical effect of two groups. Results The undetectable rate of HBV-DNA in the study group after 12 weeks of treatment and after 24 weeks of treatment were significantly better than those in the control group (P <0.05). HBV-DNA of the two groups at 108th week was not measurable (P> 0.05). The rate of HBeAg disappearance and HBeAg / anti-HBeAg seroconversion in the study group were better than those in the control group (P <0.05). The study group The incidence of bad hair was slightly lower than that of the control group, but the difference was not statistically significant (7.14% vs 16.04%, P> 0.05). Conclusion Tenofovir treatment in patients with chronic hepatitis B can effectively reduce the incidence of drug resistance and improve the antiviral effect, which deserves clinical promotion.